BMY
Bristol-Myers Squibb Company trades as BMY and has a market capitalization of $118.31 B, making it the #136 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $48.19B, down 0.2% from the prior year and net income of $7.05B. This page tracks Bristol-Myers Squibb Company through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Bristol-Myers Squibb Company's revenue grew from $19.43B to $48.19B, a compound annual growth rate of 10.6%. Net profit margin compressed from 22.9% to 14.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Employee stock plan | S-8 | 2026-05-08 |
| Major company event | 8-K | 2026-05-08 |
| Insider trade | 4 | 2026-05-05 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-17 |
| Insider trade | 4 | 2026-04-02 |
Download this Press ReleasePDF Format (opens in new window)()
Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2025 on Thursday, February 5, 2026.
The largest companies sharing Bristol-Myers Squibb Company's SEC industry classification (pharmaceutical preparations).
Bristol-Myers Squibb Company (BMY) has a market capitalization of $118.31 B as of 2026-07-09, ranking #136 among US-listed companies.
Bristol-Myers Squibb Company reported revenue of $48.19B for fiscal year 2025, a decrease of 0.2% year over year.
Yes. Bristol-Myers Squibb Company reported net income of $7.05B in its latest fiscal year.